DBV Technologies stock declines 2%, among the strongest drops on the SBF 120
DBV Technologies retreats in this first trading session of the week, in a Paris market nearly balanced. The Châtillon biotech finds itself among the most declining values of the broad index, despite positive momentum over one month and one year.
A 2% decline that places DBV among the strongest falls on the SBF 120 this Monday
DBV Technologies loses 2.08% to €2.45 in trading, against a last close of €2.50, placing it among the strongest declines on the SBF 120, in an index nearly flat (-0.01%). The decline remains moderate in absolute terms, but it contrasts with the recent trend: the biotech still showed a gain of 3.38% over the past week and 3.03% over the month, in line with an annual rebound of nearly 43%. Over three months, the picture is significantly heavier, with a decline of 23.13%, illustrating the high volatility of the security. The VIX rises 5.35% in trading to 15.94, without particular warning signals across the broader market.
A neutral technical configuration, with the price slightly above the 20-day MA but below the 50-day MA
On the indicator front, the security trades slightly above its 20-day moving average (€2.43, difference of +0.66%), reflecting still-positive short-term momentum despite today's decline. Conversely, it remains below its 50-day MA at €2.64 (difference of -7.35%), a threshold it has failed to breach in recent weeks. The RSI at 48 remains neutral and signals neither overbought conditions nor marked selling exhaustion.
The price is trading above the support level at €2.31, while resistance at €2.83 is well above the 50-day MA at €2.64: it is first this latter threshold that the security must breach to restart medium-term upward momentum. Over one year, the performance of nearly +43% remains nonetheless the key benchmark that distinguishes DBV Technologies in a highly volatile biotech sector.
